Promising biomarkers for predicting the response to ICI therapy include the expression of programmed death ligand-1 (PD-L1), the tumor mutational burden (TMB), and circulating tumor DNA in various types of cancer [6,7,8]. The gene discussed is CD274; the disease is cancer.